Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
about
A novel structural framework for α(1A/D)-adrenoceptor selective antagonists identified using subtype selective pharmacophoresAntipsychotic pharmacotherapy and orthostatic hypotension: identification and management.New frontiers in androgen biosynthesis and metabolism.Benign prostatic hyperplasia: from bench to clinicInvestigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasiaSilodosin is effective for treatment of LUTS in men with BPH: a systematic reviewSilodosin in the treatment of benign prostatic hyperplasiaSafety and efficacy of silodosin for the treatment of benign prostatic hyperplasiaRamelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia.Clinical feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms: a prospective study.α1-adrenergic receptor antagonists versus placebo for female lower urinary tract symptoms: A meta-analysis.Individual protomers of a G protein-coupled receptor dimer integrate distinct functional modules.D-004 ameliorates phenylephrine-induced urodynamic changes and increased prostate and bladder oxidative stress in rats.Dementia and lower urinary dysfunction: with a reference to anticholinergic use in elderly population.Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importanceEffects of Combination Treatment of Alpha 1-Adrenergic Receptor Antagonists on Voiding Dysfunction: Study on Target Organs in Overactive Bladder Rats.New Attempts to Overcome the Urinary Tract Disorders.Alpha 1-adrenoceptor pharmacome: alpha 1L-adrenoceptor and alpha 1A-adrenoceptor in the lower urinary tract.Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability.The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis.Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.Medical management of lower urinary tract symptoms in men with benign prostatic enlargement.Current pharmacological treatment options for male lower urinary tract symptoms.Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling.Management of benign prostatic hyperplasia with silodosinHormonal manipulation of lower urinary tract symptoms secondary to benign prostatic obstruction.Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity?The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.Chronic Pelvic Ischemia: Contribution to the Pathogenesis of Lower Urinary Tract Symptoms (LUTS): A New Target for Pharmacological Treatment?Symptoms Predictive for Efficacy of Naftopidil in Patients with Benign Prostate Hyperplasia.Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: does prostate size matter?Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH.Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3.A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia.Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies.Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study.The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle.Noradrenaline induces binding of Clathrin light chain A to α1-adrenoceptors in the human prostate.
P2860
Q28478109-83959667-68E0-4ADB-86B9-7F10061F38ACQ33160283-3F773A73-D457-4541-9E64-4D76A0C76B60Q34100727-E8EF151A-ADB8-4DDA-B7F0-948ACC323DA2Q34216723-4E5286C9-0679-4526-B187-1761DEC9FF1FQ34452517-5727B3D6-2637-41CB-85A4-B924E4178B1AQ34504207-4DCEB446-209E-41AA-9850-7C5C3993133DQ34625490-67DC8E65-CAF2-44FB-B1FC-AB6D6D8EB845Q34630995-66E8D4FD-1B25-484A-935F-C889B4489384Q34768114-FD0095E3-C159-47F5-9E2E-080C929EC17DQ34983752-25A3A634-B545-417B-9CE6-9314D1D4334EQ35802642-49693B78-A410-4258-BF65-335A68DDA9D6Q36317014-DCD38722-97E1-449E-8E5E-5B31A7792A57Q36451183-8FFC39F0-D6EA-496A-9ADB-B63E068ABD65Q37222701-F7E02774-BBAB-4F9B-98C0-4D5188CEF4CDQ37432103-A023AC22-5E9F-4CEA-969C-7A85010C437CQ37517854-5E44D88A-7A61-422D-AAC8-C130CEF5BB7EQ37517859-7D0D601E-64AC-497B-9390-0B009B4CA923Q37582994-76369CD7-6FEF-49CA-B4CA-30130E7DAA56Q37813129-3BFE4F6C-FE70-48DC-AEF9-33307CB8D57FQ38036912-285B58A8-5C26-44C8-B9F0-2FC4ECAD3091Q38063330-E4C621AE-8254-4FFC-A282-61A628975CABQ38098896-FB55779D-1C08-4CFC-A0C0-BB7310CF8E24Q38103891-C523BE15-2CC0-4CC2-9CBE-8E0047C7660CQ38137877-D9929EF7-C6B0-46E3-97A8-E43B54A6E470Q38160469-3E1EA234-732D-450E-B056-266C690AD599Q38205422-DF159E1B-927B-4EBC-B93C-8BA2341801D4Q38264932-AFE2AACE-F3B9-4C1F-95EC-21CFA0AB506AQ38364582-0D668A0E-3FD1-484C-94EC-E9278E06162BQ38668432-1C6F8BC3-D9DD-4987-AFD8-0300D0A4F37CQ40202933-F5712719-5865-4CFA-BE97-F0551C08FC11Q41770323-91F88701-173B-45FF-8799-EAEFF5C9C020Q41922883-725B95F0-75B8-447A-BF23-D833FD66D8ADQ42246419-1A6DFE6C-67C9-42BE-BA96-03BF5380CF08Q42565612-A60FD60F-FECE-4645-9ED8-1EBA3635C7EDQ42653540-78225DE0-DD2D-43A0-8420-2FBCA533EC5FQ42780748-1BD2C6CF-68FD-4A04-80C2-142869468DA5Q42920227-A200E836-F55D-4E38-A2C6-2D1F57FA1956Q43134460-C8EFB998-B0D0-47CE-90AD-841A9F6E9251Q44546106-4DBC2185-8170-4253-81DD-A8DB8471D21EQ46248296-E5C3EEA0-112A-4C07-A2AC-7116558AF665
P2860
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
@ast
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
@en
type
label
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
@ast
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
@en
prefLabel
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
@ast
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
@en
P2860
P1476
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
@en
P2093
Claus G Roehrborn
P2860
P304
P356
10.1111/J.1442-2042.2007.01956.X
P577
2008-03-01T00:00:00Z